Fenofibrate Eye Drop for the Treatment of Diabetic Retinopathy

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43EY026326-01
Agency Tracking Number: R43EY026326
Amount: $185,550.00
Phase: Phase I
Program: SBIR
Awards Year: 2016
Solicitation Year: 2015
Solicitation Topic Code: N
Solicitation Number: PA14-071
Small Business Information
800 RESEARCH PARKWAY STE 360, Oklahoma City, OK, 73104-3628
DUNS: 143171531
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 RONALD WASSEL
 (405) 271-2552
 dwassel@charlessonllc.com
Business Contact
 RAFAL FARJO
Phone: (405) 271-2557
Email: rfarjo@charlessonllc.com
Research Institution
N/A
Abstract
DESCRIPTION provided by applicant This Small Business Innovation Research project aims to develop an innovative eye drop formulation for the treatment of diabetic retinopathy The goal of this proposal is to develop substantial efficacy safety and pharmacokinetic data to support the clinical development of topical fenofibrate We hypothesize that topical application of fenofibrate can reduce vision loss and neovascularization in animal models of diabetes and retinal disease The goal of this proposal is to evaluate the efficacy of topical fenofibrate on preventing visual acuity loss in a rat model of streptozotocin induced diabetes We will give fenofibrate eye drops either two or four times a day for weeks We will measure the change of visual acuity over this time period The long term goal Phase is to perform safety studies and find a commercial manufacturer for the formulation PUBLIC HEALTH RELEVANCE Nearly all patients with type diabetes and andgt of type diabetic patients will develop some form of retinopathy and visual loss in their lifetime Fenofibrate is a peroxisome proliferator activated receptor alpha PPAR agonist that has been shown in both The Fenofibrate Intervention and Event Lowering in Diabetes FIELD and The Action to Control Cardiovascular Risk in Diabetes ACCORD clinical trials to reduce the progression of diabetic retinopathy in diabetic patients Oral fenofibrate appears to have limited systemic benefit in diabetic patients thus the topical application of fenofibrate for diabetic eye disease represents a more targeted and safe approach to treat diabetic retinopathy

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government